258 related articles for article (PubMed ID: 33570156)
1. Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells.
Liu YK; Jia YJ; Liu SH; Shi HJ; Ma J
Histol Histopathol; 2021 May; 36(5):535-545. PubMed ID: 33570156
[TBL] [Abstract][Full Text] [Related]
2. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
3. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
4. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
5. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816
[TBL] [Abstract][Full Text] [Related]
6. A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.
Bai Y; Li LD; Li J; Chen RF; Yu HL; Sun HF; Wang JY; Lu X
Int J Oncol; 2020 Jan; 56(1):301-314. PubMed ID: 31746425
[TBL] [Abstract][Full Text] [Related]
7. [Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].
Li Z; Wang Q; Zhang W; Yang Z; Li L
Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):854-60. PubMed ID: 26887775
[TBL] [Abstract][Full Text] [Related]
8. Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.
Bahar E; Kim JY; Kim HS; Yoon H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076245
[TBL] [Abstract][Full Text] [Related]
9. MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells.
Ren L; Xiao L; Hu J
J Huazhong Univ Sci Technolog Med Sci; 2007 Dec; 27(6):721-4. PubMed ID: 18231753
[TBL] [Abstract][Full Text] [Related]
10. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
Zou W; Ma X; Hua W; Chen B; Cai G
Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of microRNA-630 inhibits cell proliferation and invasion and enhances chemosensitivity in human ovarian carcinoma.
Zou YT; Gao JY; Wang HL; Wang Y; Wang H; Li PL
Genet Mol Res; 2015 Jul; 14(3):8766-77. PubMed ID: 26345808
[TBL] [Abstract][Full Text] [Related]
12. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
Zhu H; Yun F; Shi X; Wang D
Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA 1301 inhibits cisplatin resistance in human ovarian cancer cells by regulating EMT and autophagy.
Yu JL; Gao X
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1688-1696. PubMed ID: 32141535
[TBL] [Abstract][Full Text] [Related]
14. ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma.
Kim JY; Bahar E; Lee JY; Chang S; Kim SH; Park EY; Do SI; Yoon H; Kim HS
Cell Death Dis; 2022 Mar; 13(3):239. PubMed ID: 35293383
[TBL] [Abstract][Full Text] [Related]
15. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
[TBL] [Abstract][Full Text] [Related]
16. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
Shi L; Yu H; Zhang W; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
Zhang C; Wang M; Shi C; Shi F; Pei C
Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
[TBL] [Abstract][Full Text] [Related]
18. FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway.
Liu YK; Jia YJ; Liu SH; Ma J
Cancer Chemother Pharmacol; 2021 Mar; 87(3):405-414. PubMed ID: 33392640
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Accumulation of Cisplatin in Ovarian Cancer Cells from Combination with Wedelolactone and Resulting Inhibition of Multiple Epigenetic Drivers.
Sarwar S; Alamro AA; Alghamdi AA; Naeem K; Ullah S; Arif M; Yu JQ; Huq F
Drug Des Devel Ther; 2021; 15():2211-2227. PubMed ID: 34079223
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]